FOLLOWING stories of Australian pharmaceutical manufacturer Phebra supplying the US with sodium bicarbonate injectable to manage a hospital supply shortage, and pricing at up to 10 times local cost (PD Tues), the company has released a clarifying statement.
Phebra says it "is manufacturing the Sodium Bicarbonate Injection under contract for a US supplier and is not responsible for price setting in the US market."
The short supply was the result of Pfizer recalling batches due to fears of manufacturing contamination of some injectables.
The company also stressed that its US manufacturing agreement will not impact on the manufacture and supply of sodium bicarbonate injection to the Australian market.
Phebra ceo Dr Mal Eutick said the company was pleased that it was able to respond quickly to alleviate the critical shortage of the medicine in the US.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Jun 17
